DraftUnitedHealthcarePolicy CS086IN.11

Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Indiana Only)

This policy governs coverage and medical necessity for occipital nerve injections, blocks, neurolytic ablation, and related procedures for members in Indiana (age-specific notes included). It specifies which procedures are considered proven/medically necessary versus unproven/not medically necessary for occipital neuralgia and headache disorders.

Policy Summary

PayerUnitedHealthcare

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Indiana Only)

Policy CodePolicy CS086IN.11

Change TypeMaterial content added and operational edits (coverage for malignant head/neck ablation addeddefinitions addedInterQual referral removed)

Effective DateNov 1, 2025

Next Review DateN/A

Key ActionDocument prior conservative therapy and an objective short-term response to diagnostic occipital nerve block when requesting repeat or invasive interventions.

SourceLink

POLICY UPDATE CHANGES

Added language indicating occipital nerve ablation (destruction by neurolytic agent) is proven and medically necessary for treating pain due to malignancy involving the head and neck.

Removed instruction to refer to the InterQual ® CP: Procedures, Neuroablation, Percutaneous for medical necessity clinical coverage criteria for occipital nerve ablation for severe cancer pain due to malignancy involving the head and neck.

Added definitions for the Migraine Disability Assessment Test (MIDAS) and the Migraine-Specific Quality of Life Questionnaire (MSQ).

Updated Clinical Evidence and References sections to reflect the most current information.

Archived previous policy version CS086IN.10.

Indiana-onlystate applicability

1material change (ablation)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Adults (18+)primary age group

≥8unproven procedures listed

3.74 ptsmean pain reduction (GONB)

Coverage Criteria — Occipital Nerve Procedures

Covered for malignancy-related pain; reference InterQual for ablation

Summary coverage stance for adults and children:

Covered interventions for malignancy-related head/neck pain: Injection of local anesthetics and/or steroids as greater occipital nerve blocks are proven and medically necessary for treating pain due to malignancy involving the head and neck; occipital nerve ablation for severe cancer pain should follow referenced InterQual criteria.

See InterQual CP: Procedures, Neuroablation, Percutaneous for detailed criteria.

Unproven / Not Medically Necessary

Declared unproven and not medically necessary for diagnosing and/or treating occipital neuralgia or headaches due to insufficient evidence:

Unproven / Not Medically Necessary Procedures: Injection of local anesthetics and/or steroids used as greater occipital nerve blocks (in the contexts listed), neurostimulation or electrical stimulation, occipital neurectomy, partial posterior intradural C1–C3 rhizotomy, radiofrequency ablation (thermal or pulsed) or denervation, rhizotomy of C1–C3 spinal dorsal roots, surgical decompression of the second cervical nerve root and ganglion, and surgical decompression of the greater occipital nerve are considered unproven and not medically necessary for diagnosing or treating occipital neuralgia or headaches due to insufficient evidence.

Listed explicitly in the policy as unproven/not medically necessary.

Short-term therapeutic benefit

Evidence-supported scenarios where GONB shows short-term benefit (from randomized trials and meta-analyses):

Clinical indications with reported short-term benefit: Greater occipital nerve block (GONB) has demonstrated statistically significant short-term reductions in pain severity and headache frequency in randomized trials and meta-analyses for conditions including migraine (episodic and chronic), cluster headache, cervicogenic headache, and post-dural puncture headache; effect sizes are largest in minutes to weeks after injection.

See pooled reductions in pain severity and headache days reported in multiple meta-analyses (chunks 18,21,29,34).

Evidence limitations for chronic use

Limitations and implications for ongoing/repeat therapy:

Limitations to routine chronic use: Evidence for long-term or chronic preventive benefit of repeated GONB is limited or low quality; systematic reviews and HTAs conclude there is little to no evidence supporting chronic use and call for larger, longer RCTs to define durability and optimal role.

May justify restricting repeat/chronic coverage absent documented short-term response and failure of conservative therapies (chunks 27,21,29).

Surgery: insufficient evidence

Surgical interventions for occipital neuralgia/cervicogenic headache:

Surgical treatments: Available evidence is insufficient to conclude that surgical procedures (neurectomy, nerve decompression, neuroplasty, dorsal root section, rhizotomy) are effective for occipital neuralgia or cervicogenic headache; long-term efficacy is not established and randomized controlled trials are lacking for many techniques.

Systematic reviews and evidence briefs report low-quality, heterogeneous studies and recommend further RCTs (chunks 36,37).

Coverage logic based on evidence strength

Evidence-summary coverage considerations

Surgical decompression/neurectomy/neuroplasty: Evidence is insufficient to conclude effectiveness or durable benefit for many surgical procedures; high-quality randomized data are generally lacking.

Hayes and systematic reviews note lack of RCTs and low-quality evidence (chunks 36,40).

Radiofrequency (RFA/PRF): RFA and pulsed RF show mixed evidence: some studies and one RCT suggest short- to medium-term benefit for selected targets (e.g., C2 DRG, GON) while other evidence reviews find insufficient high-quality data and heterogeneity in methods and outcomes.

See mixed results from RCTs, cohort reviews, and Hayes briefs (chunks 46,49,51).

Patient selection considerations: Better outcomes in the literature are associated with patients who had positive responses to diagnostic occipital nerve blocks or C2 DRG blocks and who had failed conservative therapies; certain clinical features (longer headache duration, radiation patterns) predict poorer surgical outcomes.

Selection signals derived from systematic reviews and observational studies (chunks 44,55).

Selection / candidate criteria reported in studies

Evidence-based selection characteristics reported in the literature that are relevant to coverage decisions

Typical selection criteria used in studies: Study populations commonly had prior failure of conservative therapy AND, for RFA/PRF, a positive diagnostic block response (frequently ≥50% pain relief) prior to ablation; for neurostimulation, a successful temporary trial was typically required before permanent implantation.

Derived from retrospective reviews and implantation studies reporting trial responses (chunks 55,67).

Outcomes and evidence limitations

Reported outcomes and limitations informing coverage assessment

Reported effectiveness signals: Systematic reviews and case series report large reductions in pain scores and high reported success rates for some ablation and decompression procedures (e.g., reported ablation success ~85% in some series); pulsed RFA and other modalities report variable duration of benefit (months), and some neurostimulation studies report meaningful reductions in monthly migraine days.

Promising signals exist but are limited by study quality and heterogeneity (chunks 54,56,60).

Evidence limitations: Most studies are small, observational, heterogeneous in methods and at risk of bias; high-quality randomized evidence is limited for many modalities (ONS, PRF, RFA), which constrains definitive coverage determinations.

Multiple reviews highlight low certainty and need for RCTs (chunks 54,56,60).

Implied coverage criteria for neurostimulation therapies

Coverage is generally aligned with specialty guidance and common trial-selection practices for invasive neurostimulation:

Permanent ONS candidate selection: Candidate for permanent occipital nerve stimulation (ONS) typically has a medically refractory condition (e.g., chronic migraine or occipital neuralgia), documented failure of conservative and medical therapies, and demonstrated a positive temporary trial—commonly defined as ≥50% pain reduction—before permanent implantation.>=50% pain reduction on temporary trial

Most ONS studies and HTAs report trial-based selection criteria; specialty guidance supports diagnostic blockade prior to neurotomy (chunks 74,90).

Noninvasive neuromodulation consideration: Noninvasive neuromodulatory devices (e.g., REN, TENS, PENS, eTNS) may be offered to patients with inadequate response to or intolerance of pharmacologic therapy or those preferring nondrug options; guideline bodies support offering devices to patients with confirmed migraine though evidence strength varies.

AHS guidance supports offering neuromodulatory devices; evidence varies across devices (chunk 87).

Occipital radiofrequency neurotomy preconditions:

Guideline-based selection statements

Guideline-based coverage considerations reflected in this portion of the document:

Occipital radiofrequency neurotomy (RFN) candidates: RFN may be offered when the occipital nerves have been identified as the etiology of pain by diagnostic occipital nerve block, other etiologies have been excluded with MRI and/or CT, and diagnostic blockade precedes RFN—consistent with ASPN guidance (GRADE II-2 C).

Imaging to rule out other causes and diagnostic block preceding RFN are recommended (chunk 90).

Occipital nerve stimulation (ONS) candidacy: ONS may be considered for medically refractory occipital neuralgia per Congress of Neurological Surgeons guidance (Level III) and related society statements, but evidence is limited; use is typically in specialized centers with documentation of failure of conservative/medical therapies and governance arrangements as recommended by NICE.

ONS evidence is limited and NICE recommends special arrangements for governance/consent/audit/research (chunks 91,95,100).

This policy identifies a set of procedures that UnitedHealthcare considers unproven and not medically necessary for diagnosing or treating occipital neuralgia and related headache disorders because the available evidence does not demonstrate consistent, durable benefit. Examples explicitly listed include greater occipital nerve blocks (GONBs) in the excluded contexts, neurostimulation or electrical stimulation, occipital neurectomy, C1–C3 rhizotomy, radiofrequency ablation (thermal or pulsed), and surgical decompression procedures. These interventions are subject to denial when billed for the excluded indications unless compelling, plan-specific documentation justifies otherwise.

Systematic reviews and HTAs find that while single or short-term GONB may provide transient symptom relief, there is little to no high-quality evidence supporting chronic, repeated GONB for long‑term prevention. Likewise, surgical procedures such as neurectomy, neuroplasty, rhizotomy, and various decompression techniques lack well‑designed randomized trials and demonstrated long‑term efficacy, so routine coverage of these surgical interventions is not supported by the evidence.

Several surgical and procedural approaches (for example, neuroplasty, auriculotemporal nerve decompression, and other trigger‑site decompression techniques) do not have adequate peer‑reviewed randomized controlled trial data or robust comparative evidence. The policy therefore treats these procedures as unsupported by high‑quality evidence for routine treatment of occipital neuralgia or cervicogenic headache.

The literature on invasive neurostimulation (including occipital nerve stimulation and cervical spinal cord stimulation) contains small, heterogeneous studies with methodological limitations and variable responder rates. No well‑designed, consistent body of RCT evidence establishes long‑term effectiveness across indications, creating an evidence gap that limits routine coverage decisions for many neurostimulation applications.

Specifically for occipital nerve stimulation (ONS), evidence for certain indications such as chronic cluster headache is very limited and low quality; safety concerns and complication rates (including device infection or removal) are reported. NICE and other bodies note short‑term efficacy but recommend that ONS be used only with special arrangements for clinical governance, informed consent, audit, or research due to insufficient evidence about long‑term outcomes.

Guidance from NICE indicates that some electrical stimulation procedures should be offered only under special arrangements (clinical governance, consent, audit, or research) when evidence is limited. The policy aligns with these caveats, disfavouring routine use of neuromodulation outside of settings that can provide appropriate governance, outcome tracking, and informed shared decision making.

Providers may be asked to follow external utilization review tools or clinical pathways when applicable. Although earlier language referenced InterQual criteria for neuroablation in cancer‑related pain, the policy history documents removal of the InterQual referral instruction; providers should nonetheless be prepared to supply documentation that meets plan or tool requirements when prior authorization or third‑party review is used.

The policy references a broad set of injection, neurostimulation, and electrical modalities reviewed in the evidence base, including greater occipital nerve blocks (GONB), diagnostic occipital nerve blocks, pulsed radiofrequency (PRF) and C2 DRG pulsed RFA, radiofrequency ablation (RFA)/neurotomy, occipital nerve stimulation (ONS), cervical spinal cord stimulation (cSCS), transcutaneous or remote electrical neuromodulation (REN), TENS/PENS, and sphenopalatine ganglion (SPG) stimulation. Many device and procedure types are discussed in the clinical evidence and coding sections.

Repetitive or chronic GONB for long‑term prevention is not supported by high‑quality evidence; systematic reviews conclude that benefit is typically short‑term and that larger, longer randomized trials are needed. As a result, repeating GONB for chronic prevention generally requires documentation of an initial short‑term response and failure of standard conservative therapies before considering ongoing repeats.

Surgical procedures such as occipital neurectomy, nerve decompression (supraorbital, supratrochlear, zygomaticotemporal, or greater occipital nerve), and various neurectomy/neuroplasty operations have not demonstrated consistent effectiveness in randomized trials. The policy treats these surgical approaches as not established for routine treatment of occipital neuralgia or cervicogenic headache.

Across many interventional and device‑based procedures reviewed (including neurostimulation, electrical stimulation, and some ablation techniques), the evidence base is characterized by small sample sizes, observational designs, and methodological heterogeneity. The relative lack of randomized controlled trials limits definitive conclusions about effectiveness for many applications.

For chronic cluster headache, the body of evidence for ONS is very small and generally of poor quality; systematic reviews and HTAs conclude that current data are insufficient to establish routine effectiveness, yielding a cautious coverage stance for ONS in this indication.

Conservative Treatment and Prior Therapy Requirements

Prior Authorization

Prior Authorization, Documentation, and Denial Risks

Prior authorization is commonly required for many occipital nerve and related interventional procedures (see affected codes in the billing/coding section). Providers should verify member plan benefit terms and obtain prior authorization when indicated. Prior authorization for radiofrequency ablation (RFA) or pulse radiofrequency (PRF) procedures is likely required and generally hinges on documentation of prior conservative care failure and a documented diagnostic block response. Device-based therapies (e.g., implanted neurostimulation systems, peripheral nerve stimulators) require additional device and clinical justification in the prior authorization request, including device model, laterality, lead/implant details, and indication-specific rationale. Requests lacking required clinical documentation, objective diagnostic criteria, or evidence of prior trial of conservative therapies may be denied. Unproven procedures, procedures with low-quality evidence, or procedures with a high risk of complications are at increased risk for denial.

Check plan benefit terms and member coverage; benefit-term alignment is required before authorization.
Prior authorization likely required for RFA/PRF and for implanted neuromodulation devices.
Prior authorization requests for device implantation must include device-specific justification and procedural details (device model, lead type/positioning, laterality, implantation site, and anticipated programming parameters).
Denial risk increases for procedures considered unproven or investigational, for procedures supported only by low-quality evidence, and when complication risk is elevated without clear benefit.

Provider Actions, Documentation, and Authorization

Prior Authorization

Prior authorization may apply — referenced procedure/device codes

Some listed procedure and device CPT/HCPCS/diagnosis codes are provided for reference; codes marked with an asterisk were not managed for medical necessity review in Indiana at policy effective date—check the Indiana prior authorization list for current requirements.

Codes include: 64405, 64553, 64555, 64568, 64570, 64575, 64590, 64596, 64597, 64598, 64633, 64634, 64722, 64744, 64771, 64999, A4540, L8679, L8680, L8685, C76.0, G89.3 (see policy code tables).
Refer to UnitedHealthcare Indiana prior authorization list for which codes require prior authorization.

Prior Authorization

Prior authorization may be required for repeated/chronic GONB

Given limited evidence for long‑term benefit of repeated GONB, prior authorization for repeat or chronic GONB may require documentation of prior conservative therapy failure and objective short‑term response to an initial block.

Document initial GONB short-term response (e.g., pain reduction up to 24–48 hours or weeks).
Document prior conservative therapies and reasons for continuing blocks.

CPT / HCPCS / ICD Coding and Device Product Codes

Applicable CPT/HCPCS/Diagnosis Codesmixed

63185	Laminectomy with rhizotomy; 1 or 2 segments.
63190	Laminectomy with rhizotomy; more than 2 segments.
64405	Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve.
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve.
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64568	Open implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64570	Removal of cranial nerve neurostimulator electrode array and pulse generator.
64575	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection.
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.

1–10 of 24

1/3

FDA product codes for RFA devicesmixed

GXD	FDA product code: radiofrequency lesion generators
GXI	FDA product code: radiofrequency lesion probes

FDA product codes / clearances for electrical stimulation devicesmixed

GZF	FDA product code for certain electrical stimulation devices
GZB	FDA product code for certain electrical stimulation devices
PCC	FDA product code for certain electrical stimulation devices
K203181	Nerivio Migra 510(k)/De Novo ID (reference K203181)

Definitions and Abbreviations

Cervicogenic Headache

DefinitionReferred pain perceived in the head from a source in the neck; caused by a disorder of the cervical spine and its bony, disc, and/or soft tissue components.

Typical diagnostic referenceDiagnosis commonly relies on International Headache Society (IHS) and Cervicogenic Headache International Study Group criteria as noted in policy documentation.

Clinical implicationMay be managed with conservative therapies and targeted interventions when cervical spine pathology is identified.

MIDAS (Migraine Disability Assessment Test)

DefinitionMIDAS (Migraine Disability Assessment Test): a questionnaire totaling days from questions 1–5 to measure headache-related disability; score categories: 0–5 little/no, 6–10 mild, 11–20 moderate, 21+ severe.

Use

Frequency and Repeat Treatment Notes

Greater occipital nerve blocks (frequency context)

Study patternsStudies used single and repeated GONB injections; examples include weekly x3 series and four‑weekly injections for 12 weeks in randomized trials.

Policy frequency statementNo explicit policy frequency limit for GONB is specified in this fragment; study protocols vary.

ImplicationRepeat or chronic GONB may require documentation of prior short‑term response and conservative therapy failure when considered for ongoing use.

GONB frequency notes from studies

Trial regimens reportedExamples reported: four‑weekly bilateral GONB for 12 weeks (chronic migraine trial) and once‑weekly GONB for three weeks with possible monthly maintenance per clinical response.

Evidence note

Imaging and Procedural Guidance

Billing Rule

Document imaging guidance for neurostimulator/ablation procedures

Imaging guidance is referenced in CPT descriptors for neurostimulator insertion, neurolytic destruction, and peripheral electrode placement; include imaging guidance details in procedural documentation although the policy does not state a separate imaging requirement.

Document imaging guidance used (fluoroscopy, CT, ultrasound) when performing devices/ablation.
Report imaging findings and guidance technique in operative notes.

Documentation Required

Ultrasound guidance for GONB is optional — document technique if used

Ultrasound guidance was used in GONB studies and is described as an optional technique; document if ultrasound guidance was used for blocks, but policy does not mandate it.

Not Covered / Experimental Procedures

The policy explicitly lists neurostimulation and other electrical stimulation procedures for occipital neuralgia and headache among interventions deemed not covered (unproven/not medically necessary) for routine use. Billing for these modalities in excluded contexts is likely to result in non‑coverage without strong, plan‑specific justification.

Background and Evidence Summary

Cervicogenic headache and occipital neuralgia are described as conditions originating from the upper cervical spine or occipital nerve regions; diagnosis relies on established clinical criteria (for example, IHS and Cervicogenic Headache groups) and treatment options range from conservative measures and local injections to ablative and neuromodulatory procedures.

Policy Revision History and Changes

2025-11-01material_changeLatest

Added language that occipital nerve ablation (destruction by neurolytic agent) is proven and medically necessary for treating pain due to malignancy involving the head and neck; added MIDAS and MSQ definitions; removed instruction to refer to the InterQual CP for percutaneous neuroablation.

This policy replaces and archives the prior version CS086IN.10 and includes a material change effective 11/01/2025 noting that occipital nerve ablation for pain due to malignancy of the head and neck is now described as proven and medically necessary; the policy history documents that InterQual referral language was removed.

Policy Summary

PayerUnitedHealthcare

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Indiana Only)

Policy CodePolicy CS086IN.11

Change TypeMaterial content added and operational edits (coverage for malignant head/neck ablation addeddefinitions addedInterQual referral removed)

Effective DateNov 1, 2025

Next Review DateN/A

Key ActionDocument prior conservative therapy and an objective short-term response to diagnostic occipital nerve block when requesting repeat or invasive interventions.

SourceLink

On This Page

Diagnostic occipital nerve blockade should precede radiofrequency neurotomy (RFN), and imaging (MRI/CT) should be used to rule out alternative etiologies before RFN, consistent with ASPN best-practice statements.

ASPN recommends diagnostic blocks and pre-procedural imaging (chunk 90).

Evidence limitations (small studies, observational designs, inconsistent outcomes) may influence coverage determinations and prior authorization decisions.

Prior authorization may require documentation that conservative treatments were tried and failed and that the patient had an adequate diagnostic block response before proceeding to ablation or neuromodulation.

Conservative Care and Diagnostic Block Requirements

Conservative therapy expectations and diagnostic block guidance

Trial of pharmacologic therapy or documented intolerance/contraindication before invasive device therapy is generally expected.

Document prior diagnostic block response and prior response documentation for subsequent procedures.

Documentation Required

Implanted Neuromodulation: Authorization and Selection

For implanted neuromodulation (peripheral nerve stimulation or occipital nerve stimulation/epidural systems) ensure that patient selection follows guideline recommendations: medically refractory disease after adequate conservative therapy, clear diagnostic criteria for occipital neuralgia or cervicogenic headache, documented positive response to a diagnostic or trial stimulation (when applicable), and multidisciplinary evaluation by clinicians experienced in headache or pain management. Prior authorization for neurostimulation often requires documentation of prior medication trials, prior injections/blocks and their responses, and objective outcome measures (pain scores, disability scales). The governance and oversight recommended by NICE and specialty societies (e.g., AHS, Congress of Neurological Surgeons, VA/DoD) advise that some neuromodulatory procedures be performed under special arrangements for clinical governance, consent, audit, or research when evidence is limited.

Confirm multidisciplinary evaluation and appropriate specialist involvement (e.g., pain specialist, neurologist, neurosurgeon) for consideration of implanted devices.
Provide documentation of prior trials (medication and non-medication), diagnostic blocks, and any trial stimulation responses.
When evidence is limited, perform procedures with appropriate governance, informed consent, and outcome audit as recommended by guidelines (NICE, specialty societies).

Suggested and Required Documentation to Support Medical Necessity

Required supporting clinical documentation

Required supporting documentation to establish medical necessity and to reduce denial risk.

Prior Authorization

Expect prior authorization for RFA/PRF with supporting documentation

Prior authorization is likely required for RFA/PRF procedures and may require documentation of prior conservative treatments and a positive diagnostic block response before approval.

Include documentation of failed conservative care and diagnostic block responsiveness.
Provide clinical rationale referencing RCT or study-supported indications when available.

Prior Authorization

Authorization typically requires evidence of conservative-care failure and trial response

Prior authorization for neurostimulation and device-based interventions commonly requires documentation of prior conservative care failure and objective trial response (e.g., successful temporary trial before permanent ONS).

Document number and types of prior preventive treatments tried and failed.
Include temporary trial results (commonly ≥50% pain reduction) when applicable.

Prior Authorization

Temporary trial and diagnostic block required before permanent procedures

Permanent ONS implantation is generally preceded by a successful temporary trial (commonly ≥50% pain reduction) and diagnostic occipital nerve blockade is recommended prior to occipital radiofrequency neurotomy; document trial outcomes and diagnostic block findings for authorization.

Record temporary trial percent pain reduction and duration.
Include diagnostic occipital nerve block results when planning RFN.

Prior Authorization

Include device and FDA product information in prior authorization

When prior authorization applies for device implantation or RFA procedures, include device model/manufacturer and FDA product code(s) (e.g., GXD/GXI for RFA devices; GZF/GZB/PCC for electrical stimulation devices) and clinical justification tied to guideline recommendations.

Provide FDA product codes or 510(k) references for the device used.
Attach device-specific clinical rationale and trial results supporting implantation.

Prior Authorization

Expect utilization/prior authorization tools (e.g., InterQual) to be used

UnitedHealthcare may use third‑party tools (such as InterQual) to assist in administering benefits; be prepared to satisfy the plan's prior authorization tools or processes and provide required documentation.

Check whether InterQual or other utilization tools are being applied for the requested service.
Follow the plan's submission requirements and provide referenced clinical criteria when requested.

Prior Authorization

Follow referenced criteria for cancer-related occipital ablation

For occipital nerve ablation to treat severe cancer pain of the head and neck, follow referenced step/criteria (previously InterQual) and document that criteria for ablation in malignancy-related pain are met.

Document malignant diagnosis involving head/neck (e.g., C76.0) and that pain is due to malignancy.
Include justification that ablation is for cancer-related pain per the referenced criteria.

Step Therapy

Conservative-first approach expected before repeat/chronic interventions

The policy context implies a conservative-first approach: attempt and document standard conservative or targeted medical therapy before repeated or chronic use of GONB, given limited evidence for chronic preventive benefit.

Record all conservative treatments tried (medications, physical therapy, behavioral interventions).
Document reasons for escalation beyond conservative care.

Documentation Required

Document conservative steps taken before surgery/ablation

Prior to surgery or ablation, document completed conservative steps and diagnostic blockade results; evidence and reviews emphasize performing and recording these steps before invasive procedures.

List conservative therapies attempted and durations.
Include diagnostic block outcomes that informed the decision.

Note

Include complete clinical justification and documentation

No specific summary provided in inventory; ensure all clinical justification and required documentation described elsewhere in the policy are included in any submission.

Cross-check policy sections for applicable documentation requirements.
Provide any requested clinical evidence or trial data.

Documentation Required

Document diagnosis using accepted clinical criteria

Support the diagnosis using accepted criteria (e.g., IHS, Cervicogenic Headache International Study Group) and document symptom characteristics, prior conservative therapies, and rationale for the planned intervention.

Record diagnostic criteria used (IHS/Cervicogenic Headache group).
Document detailed headache history, exam findings, and prior treatments.

Documentation Required

Provide indication, prior therapies, and short-term outcomes

To support medical necessity, include indication (migraine subtype, PDPH, cluster headache), prior conservative therapies tried, procedure details, and short‑term outcome measures (pain scores, headache days) in documentation.

Attach short-term outcome data after prior injections (e.g., NRS/NRS-11 at defined timepoints).
List indications and prior therapy timelines.

Documentation Required

Document prior positive treatment responses

Document prior positive diagnostic/therapeutic responses (for example response to diagnostic occipital nerve block, Botox, or C2 DRG block) as these are commonly associated with better outcomes and are expected in selection for advanced interventions.

Include objective percent pain relief and duration after diagnostic procedures.
Note prior Botox response if relevant to surgical candidacy.

Documentation Required

Document diagnostic block response (e.g., ≥50% relief)

Record the result of prior diagnostic block(s); studies associate definite positive responses (e.g., ≥50% pain relief after C2 DRG block) with better outcomes after pulsed RFA and similar procedures.

Record percent pain relief and timepoint (e.g., 24 hours, 1 week).
Include the technique and imaging guidance used for the block.

Documentation Required

Document failures of conservative/medical therapies

Document prior conservative treatment failures; neurostimulation studies typically required multiple prior failed preventive treatments and documentation of medically refractory disease.

List preventive medications and nonpharmacologic therapies tried and durations.
Provide objective measures of refractoriness (e.g., headache days, MIDAS score).

Documentation Required

Include temporary trial and diagnostic block documentation for implants

Provide required supporting documentation for device implantation or permanent neurostimulation: temporary trial results (commonly ≥50% pain reduction), diagnostic block findings, and objective outcome measures used to justify permanent implantation.

Include temporary trial percent improvement and duration.
Attach diagnostic occipital nerve block reports when applicable.

Documentation Required

Provide procedural, imaging, and device details

Document procedural details and device information: diagnostic occipital nerve block results, pre-procedure imaging (MRI/CT) used to rule out other etiologies prior to RFN, and device model/manufacturer with FDA product code/clearance when applicable.

Attach MRI/CT reports ruling out alternative causes before RFN.
Provide device model, manufacturer, and FDA product code or 510(k) reference.

Note

Verify plan benefit terms and state-specific requirements

Check federal, state, or contractual benefit plan coverage terms before proceeding; in case of conflict, those benefit terms govern coverage decisions and may affect prior authorization requirements.

Verify plan-specific prior authorization and benefit limitations.
Confirm state-specific managed code lists for Indiana.

Denial Risk

Denial risk for procedures listed as unproven/not medically necessary

Billing or coverage may be denied when procedures specifically listed as unproven/not medically necessary are billed for indications the policy disallows (e.g., many surgical decompressions, neurostimulation, routine chronic repeated GONB without documented response).

Avoid billing the listed unproven procedures for occipital neuralgia/headache indications without clear supporting documentation.
Provide robust justification if requesting coverage for an otherwise listed unproven procedure.

Denial Risk

Evidence limitations for chronic GONB may lead to denial

Insufficient high‑quality evidence for chronic use of GONB and lack of durable benefit for chronic therapy may be a basis for denial of ongoing/repeat interventions unless documentation shows short‑term response and failed conservative therapy.

Document objective short-term benefit and rationale for repeat blocks.
Document failed conservative therapies to support repeat interventions.

Denial Risk

Insufficient evidence for some surgical procedures may trigger denial

Procedures lacking sufficient evidence (for example neuroplasty and many decompression techniques) are at risk for non-coverage or denial when evidence of effectiveness is insufficient; include high-quality supporting data if requesting coverage.

Attach peer-reviewed evidence supporting effectiveness if available.
Recognize that absence of RCTs or high-quality studies increases denial risk.

Denial Risk

Low evidence quality for some interventions increases denial risk

Low level of evidence and significant risk of bias in much of the literature may lead to medical necessity denials for some ablation or surgical interventions when higher-quality evidence is required.

Provide context on study quality when submitting evidence.
Anticipate requests for stronger comparative data or RCT evidence.

Denial Risk

Complication risk and low-quality evidence can contribute to denial

Risk of complications from device-based therapies (lead migration, infection, hardware dysfunction, need for removal) and limited-quality evidence for some indications may lead to denials or to requirement for additional justification.

Document anticipated benefit versus device-related risks in the plan of care.
Include prior trial results and complication mitigation strategies.

Denial Risk

Diagnostic block required before RFN — omission risks denial

Specialty guidance recommends diagnostic occipital nerve blockade should precede occipital radiofrequency neurotomy; absence of prior diagnostic blockade could lead to nonconcordance with guideline-recommended practice and affect coverage.

Include documented diagnostic occipital nerve block prior to RFN requests.
Provide block technique, percent relief, and duration in the record.

Denial Risk

Ensure governance and documented refractoriness for neuromodulation

Neuromodulation and ONS should be reserved for medically refractory patients and used under special arrangements (governance/consent/audit/research) per NICE and other guidance; lack of documented medical refractoriness or governance arrangements may affect coverage.

Document prior treatment failures and any special governance/consent/audit frameworks in place.
Consider tertiary-center referral or formal research/governance arrangements for ONS.

Note

Align requests with applicable benefit plan terms

Coverage decisions must align with federal, state, or contractual benefit plan terms; failure to reference or comply with these terms may result in denial even if the intervention aligns with policy statements.

Confirm applicable contractual or state-specific coverage rules before proceeding.
Provide plan-specific documentation when submitting prior authorization requests.

Used to quantify impact of headaches and guide clinical discussion when MIDAS score is ≥6.

SourceNational Headache Foundation guidance referenced in policy definitions.

MSQ (Migraine-Specific Quality of Life Questionnaire)

DefinitionMSQ (Migraine-Specific Quality of Life Questionnaire): a 14-item self-report instrument assessing role, emotional, and social functioning; items rated on a 6-point Likert scale.

UseAssesses migraine impact on quality of life to inform treatment decisions and outcome measurement.

ValidityReported as widely used and validated across languages and populations (Giannouli et al. 2024).

Neurectomy

DefinitionNeurectomy: partial or total excision or resection of a nerve.

ContextStudied as a surgical option for occipital neuralgia and related headaches but evidence is insufficient to establish effectiveness.

Coverage notePolicy identifies occipital neurectomy among procedures considered unproven/not medically necessary for routine treatment of ON/headache due to limited high-quality evidence.

Rhizotomy

DefinitionRhizotomy: surgical section of a nerve root to relieve pain.

ContextIncludes procedures such as partial posterior intradural C1–C3 rhizotomy; long-term efficacy for ON/cervicogenic headache is not established in well-designed trials.

Coverage notePolicy lists rhizotomy among surgical interventions lacking sufficient evidence and considered unproven/not medically necessary for routine use.

GONB (Greater Occipital Nerve Block)

DefinitionGONB (Greater Occipital Nerve Block): injection of local anesthetic, often with or without corticosteroid, into the greater occipital nerve region for diagnostic or therapeutic purposes.

Evidence summaryRandomized trials and meta-analyses report short-term reductions in pain severity and headache frequency (e.g., pain reduction up to 1–6 weeks and decreased headache days in several RCTs).

Clinical practiceStudies include single and repeated injections (e.g., weekly x3 or four-weekly injections for 12 weeks); policy notes limited evidence for durable long-term preventive benefit.

Migraine surgery / neuroplasty

DefinitionMigraine surgery / neuroplasty: surgical procedures (e.g., nerve release, neurectomy, rhizotomy) aimed at decompression or modification of occipital or trigger‑site nerves.

Evidence summarySystematic reviews report limited and low-quality evidence with no RCTs for many techniques; long-term efficacy remains uncertain.

Coverage implicationPolicy considers many surgical approaches unproven or not medically necessary for routine treatment of ON/cervicogenic headache absent stronger evidence.

Neuroplasty / Neurolysis

DefinitionNeuroplasty / Neurolysis: procedures intended to free a nerve from surrounding scar or compressive tissue.

Evidence summaryEvidence for neuroplasty in occipital neuralgia is limited, lacking RCTs; systematic reviews highlight inadequate peer‑reviewed data to draw firm conclusions.

Coverage implicationPolicy notes neuroplasty among interventions with insufficient evidence and at risk for noncoverage without high‑quality supportive data.

Pulsed Radiofrequency (PRF)

DefinitionPulsed Radiofrequency (PRF): a neuromodulatory radiofrequency technique (non‑thermal lesioning) applied to occipital nerves or C2 DRG.

Evidence summarySome RCTs and observational studies report longer‑term pain reduction versus nerve block alone for select targets; durability is variable and evidence quality mixed.

Clinical notePRF has been applied to GON and C2 DRG in trials; studies report single treatments with variable follow‑up and no formal standardized repeat frequency in policy fragments.

C2 DRG pulsed RFA

DefinitionC2 DRG pulsed RFA: pulsed radiofrequency procedure targeting the C2 dorsal root ganglion for cervicogenic headache or occipital neuralgia.

Evidence summaryRetrospective and cohort studies report that ~40% of patients achieved ≥50% pain relief at six months in one series; positive response to prior C2 DRG block predicted better outcomes.

Clinical practiceProcedures are commonly performed under fluoroscopic guidance and often follow a diagnostic C2 DRG block to select candidates.

ONS (occipital nerve stimulation)

DefinitionONS (Occipital Nerve Stimulation): implantable peripheral nerve stimulation targeting occipital nerves for chronic/refractory headache disorders; typically preceded by a temporary trial.

Evidence summaryStudies and HTAs report variable responder rates (wide ranges) and a generally low‑quality evidence base; many permanent implantations are contingent on a successful temporary trial (commonly ≥50% pain reduction).

Safety considerationsReported risks include lead migration, infection, hardware complications, and potential need for additional surgery; NICE recommends use only with special arrangements for governance/audit/research.

ONS (Occipital Nerve Stimulation) - alternate entry

Alternate definitionONS (Occipital Nerve Stimulation): invasive neurostimulation implant used for refractory chronic migraine, occipital neuralgia, or cluster headache; permanent implantation usually follows a positive temporary trial.

Trial requirementMost studies selected candidates for permanent implantation after a positive temporary trial, typically defined as ≥50% pain reduction.

Guideline cautionNICE and other bodies advise limited use with special arrangements and emphasize need for further comparative data and governance.

REN / TENS / PENS / eTNS

DefinitionREN / TENS / PENS / eTNS: noninvasive or minimally invasive peripheral neurostimulation modalities studied for acute and preventive migraine treatment.

Evidence summarySystematic reviews and assessments (e.g., ECRI, Moisset et al.) report evidence for acute and some preventive benefit for specific devices (e.g., Nerivio) but note overall study quality is limited and more RCTs are needed.

Clinical roleThese modalities may be considered for patients with inadequate response to or intolerance of pharmacologic therapy; indications and evidence strength vary by device.

SPG stimulation

DefinitionSPG stimulation: sphenopalatine ganglion stimulation, an implantable therapy evaluated for acute treatment of chronic cluster headache with randomized sham‑controlled evidence.

Evidence summaryRandomized sham‑controlled trial reported higher pain relief at 15 minutes versus sham (62.5% vs 38.9%); device implantation carries surgical risks and some serious adverse events were reported.

Clinical implicationMay be considered in selected patients with chronic cluster headache but requires careful consideration of risks and governance.

Diagnostic occipital nerve block

DefinitionDiagnostic occipital nerve block: injection of local anesthetic (with or without steroid) to temporarily anesthetize occipital nerves to determine if they are the pain source and to predict response to neurotomy or other interventions.

Selection roleDiagnostic blockade is recommended before occipital radiofrequency neurotomy and is associated with better outcomes for subsequent procedures when positive (often defined as ≥50% pain relief).

EvidenceMeta-analyses and trials report diagnostic and short‑term therapeutic utility of occipital nerve blocks for predicting surgical or ablative treatment response.

Radiofrequency ablation (RFA)/Radiofrequency neurotomy (RFN)

DefinitionRadiofrequency ablation (RFA)/Radiofrequency neurotomy (RFN): percutaneous ablation technique using radiofrequency‑generated lesions applied to peripheral nerves; devices used are regulated by the FDA 510(k) process.

Evidence summaryEvidence is mixed: some systematic reviews and observational studies report substantial pain reduction and high success rates in select series, but high‑quality RCT evidence is limited and heterogeneous.

Device noteFDA product codes exist for RFA generators and probes (GXD, GXI); the procedure itself is not FDA‑regulated but devices are cleared.

Occipital nerve stimulation (ONS) / neuromodulation

DefinitionOccipital nerve stimulation (ONS) / neuromodulation: implanted or external electrical stimulation of occipital or extracranial nerves to modulate pain signaling, typically reserved for medically refractory cases.

Clinical pathwayPermanent implantation is usually preceded by a temporary trial demonstrating benefit (commonly ≥50% pain reduction); imaging and diagnostic blocks are recommended prior to some procedures.

Coverage cautionPolicy and guideline bodies (e.g., NICE) advise use under special arrangements with governance, consent, and audit due to limited long‑term outcomes and risk of complications.

MIDAS (new definition entry)

DefinitionMIDAS: Migraine Disability Assessment Test referenced as a patient‑reported outcome instrument in the policy definitions.

Scoring categoriesScore ranges: 0–5 (little/no), 6–10 (mild), 11–20 (moderate), 21+ (severe); a score ≥6 prompts discussion with a provider.

PurposeUsed to measure headache-related disability and assist treatment planning.

MSQ (new definition entry)

DefinitionMSQ: Migraine‑Specific Quality of Life Questionnaire, a 14‑item self‑report measure assessing migraine impact on role, emotional, and social functioning.

Response scaleItems rated on a 6‑point Likert scale from 1 (very poor) to 6 (very good).

Clinical useReferenced in policy as a validated outcome instrument to assess treatment impact on quality of life.

Randomized trials demonstrated reductions in headache and migraine days with repeated GONB protocols, but generalizability is limited by study populations and durations.

Policy implicationBecause study schedules vary and long‑term benefit is uncertain, authorization for repeated GONB may require documented short‑term benefit and prior conservative therapy trials.

RFA/PRF frequency notes

Frequency reportingRFA/PRF studies report single procedures with follow‑up ranges from months to years; some series report mean duration of benefit (e.g., ~254 days) after RFA.

Repeat proceduresSeveral reviews note limited data on repeat RFN sessions and call for longer follow‑up to inform repeat session recommendations.

Policy positionNo formal repeat frequency limits specified in this policy fragment; repeat treatment decisions guided by clinical response and existing guideline recommendations.

Pulsed radiofrequency frequency notes

Study observationsPulsed radiofrequency (PRF) studies commonly report single treatments with variable durability; effectiveness rates vary across indications and time points.

DurabilityObserved effectiveness at 1–6 months is often favorable, but long‑term durability is inconsistent across small studies and observational cohorts.

Policy implicationNo formal PRF frequency limits are stated in the policy fragment; repeat PRF is considered based on individual clinical response and limited evidence.

Occipital radiofrequency neurotomy frequency note

Occipital RF neurotomy frequencySeveral studies document pain relief lasting up to six months after RFN; guideline statements note need for further study to recommend repeat sessions and do not provide standardized repeat intervals.

Guideline adviceASPN best practices indicate several studies documented six months of relief; longer follow‑up needed before recommending routine repeat RFN sessions.

Policy notePolicy fragment does not specify formal repeat frequency limits for occipital RFN; clinical discretion and guideline recommendations guide repeat interventions.

RFN / RFA frequency note

General statementRFN/RFA repeat frequency is not specified in this policy fragment; evidence supports variable durations of benefit and recommends imaging and diagnostic blockade before RFN.

Observed durationsRetrospective series report mean duration of improvement (e.g., ~254 days) after RFA in some cohorts, but data are heterogeneous.

Coverage implicationDecisions about repeat RFN/RFA should be informed by prior diagnostic block response, documented clinical benefit, and guideline recommendations rather than fixed policy frequency limits in this fragment.

If ultrasound-guided, include probe location (proximal vs distal) and technique.
If anatomical landmark technique used, describe approach and rationale.

Documentation Required

Document fluoroscopy or ultrasound guidance for C2 DRG and GONB procedures

Studies of C2 DRG blocks/RFA and some GONB procedures used fluoroscopy or ultrasound guidance; when these modalities are used, document the imaging method and findings in the procedure note.

Record fluoroscopic views or ultrasound landmarks employed.
Attach imaging-confirmation images or reports when available.

Documentation Required

Document image guidance and technique for PRF/PRFT procedures

Pulsed RF/PRFT and many nerve block studies commonly used image guidance (US or CT); include imaging modality and targeting details in procedural documentation.

Specify imaging modality (US, CT) and parameters used for PRF/PRFT.
Document lesioning settings and probe placement when applicable.

Documentation Required

Obtain and document MRI/CT before occipital RFN to exclude other etiologies

Before occipital radiofrequency neurotomy, specialty guidance recommends MRI and/or CT to rule out other etiologies; include pre-procedure imaging reports in the record.

Attach MRI/CT reports that exclude alternate causes of head/neck pain.
Note that imaging is used to rule out other etiologies but is not diagnostic for ON.

Documentation Required

Document pre-procedural MRI/CT for RFN/occipital procedures

For RFN and other occipital procedures, include MRI/CT imaging used to rule out other causes of headache in pre-procedural documentation, as recommended by best-practice guidance.

Include imaging dates, modality, and relevant negative findings supporting procedure candidacy.
Document that imaging was reviewed and considered in the decision to perform RFN.